Literature DB >> 20047041

Applications of bacterial ghosts in biomedicine.

Petra Lubitz1, Ulrike Beate Mayr, Werner Lubitz.   

Abstract

Bacterial Ghosts (BG) are empty cell envelopes of Gram-negative bacteria which have been produced by E-mediated lysis. BG are devoid of cytoplasmic content and in combination with the expression of the nuclease SNUC, BG are also devoid of chromosomal and plasmid DNA. Proof of concept and proof of principle studies showed that BG candidate vaccines are highly immunogenic and in many instances induce protective immunity against lethal challenge in animal models. Due to their nature of being bacterial envelope complexes, BG are endowed with intrinsic natural adjuvant activity. BG are able to stimulate the innate and adaptive immune system without any addition of exogenous adjuvants. Although the use of plasmid encoded genetic information is essential for the final make up of BG, BG are not to be considered as genetically manipulated organisms (GMO), as they are nonliving and devoid of genetic information. The latter aspect is of great importance for safety, as no pathogenic islands or antibiotic resistance cassettes can be transferred to other bacteria by horizontal gene transfer. This is an important difference to other chemical-, heat- and pressure- or radiation-inactivated vaccine candidates, which also very often need artificial adjuvants to be added to improve their immunogenicity. The final BG vaccine preparations are freeze dried and are stable for many years at ambient temperature. BG can also be used as carrier and delivery vehicles for drugs or active substances in tumor therapy and due to specific targeting of tumor cells allow a higher specificity of treatment and a reduction of the total amount of drug per application. As carrier of enzymatic activity BG can be used for a new concept of probiotics which can synthesise active compounds from substrates of the environment where they are applied with a certain preference for the gut system. Thus, BG represent a promising technology platform for novel vaccines including combination or DNA vaccines, as drug carriers for therapeutic approaches in tumor treatment and as novel probiotics.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20047041     DOI: 10.1007/978-1-4419-1132-2_12

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  21 in total

Review 1.  The Bacterial Ghost platform system: production and applications.

Authors:  Timo Langemann; Verena Juliana Koller; Abbas Muhammad; Pavol Kudela; Ulrike Beate Mayr; Werner Lubitz
Journal:  Bioeng Bugs       Date:  2010 Sep-Oct

Review 2.  Bio-inspired, bioengineered and biomimetic drug delivery carriers.

Authors:  Jin-Wook Yoo; Darrell J Irvine; Dennis E Discher; Samir Mitragotri
Journal:  Nat Rev Drug Discov       Date:  2011-07-01       Impact factor: 84.694

3.  Protection of piglets by a Haemophilus parasuis ghost vaccine against homologous challenge.

Authors:  Mingming Hu; Yanhe Zhang; Fang Xie; Gang Li; Jianjun Li; Wei Si; Siguo Liu; Shouping Hu; Zhuo Zhang; Nan Shen; Chunlai Wang
Journal:  Clin Vaccine Immunol       Date:  2013-03-27

Review 4.  Bacterial components as naturally inspired nano-carriers for drug/gene delivery and immunization: Set the bugs to work?

Authors:  Fatemeh Farjadian; Mohsen Moghoofei; Soroush Mirkiani; Amir Ghasemi; Navid Rabiee; Shima Hadifar; Ali Beyzavi; Mahdi Karimi; Michael R Hamblin
Journal:  Biotechnol Adv       Date:  2018-02-28       Impact factor: 14.227

5.  Generation of a Novel Staphylococcus aureus Ghost Vaccine and Examination of Its Immunogenicity against Virulent Challenge in Rats.

Authors:  Nagarajan Vinod; Sung Oh; Hyun Jung Park; Jung Mo Koo; Chang Won Choi; Sei Chang Kim
Journal:  Infect Immun       Date:  2015-05-11       Impact factor: 3.441

6.  Immunological characterization of the chemically prepared ghosts of Salmonella Typhimurium as a vaccine candidate.

Authors:  Sameh Rabea; Aymen S Yassin; Aly Fahmy Mohammed; Mounir M Salem-Bekhit; Fars K Alanazi; Eman Amin Esmail; Nayera A Moneib; Abd Elgawad M Hashem
Journal:  BMC Vet Res       Date:  2022-02-18       Impact factor: 2.741

Review 7.  Advances in the development of enterohemorrhagic Escherichia coli vaccines using murine models of infection.

Authors:  Victor A Garcia-Angulo; Anjana Kalita; Alfredo G Torres
Journal:  Vaccine       Date:  2013-05-22       Impact factor: 3.641

Review 8.  Involvement of long noncoding RNAs in diseases affecting the central nervous system.

Authors:  Chiara Pastori; Claes Wahlestedt
Journal:  RNA Biol       Date:  2012-06-01       Impact factor: 4.652

Review 9.  Relevant uses of surface proteins--display on self-organized biological structures.

Authors:  Anika C Jahns; Bernd H A Rehm
Journal:  Microb Biotechnol       Date:  2011-09-09       Impact factor: 5.813

10.  Rectal single dose immunization of mice with Escherichia coli O157:H7 bacterial ghosts induces efficient humoral and cellular immune responses and protects against the lethal heterologous challenge.

Authors:  Ulrike Beate Mayr; Pavol Kudela; Alena Atrasheuskaya; Eugenij Bukin; Georgy Ignatyev; Werner Lubitz
Journal:  Microb Biotechnol       Date:  2011-11-22       Impact factor: 5.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.